Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification

• Jenny L. Soiffer,
• Alexander J. Fife,
• Shrikanth S. Gadad,
• Javier A. Laurini,
• Julia A. Elvin,
• Sara S. Isani,
• Ken Y. Lin

Affiliations

Jenny L. Soiffer

Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States; Corresponding author at: 1695 Eastchester Road, Bronx, NY 10461, United States.

Alexander J. Fife

Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States

Shrikanth S. Gadad

Center of Emphasis in Cancer, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States

Javier A. Laurini

Albert Einstein College of Medicine / Montefiore Medical Center, Department of Pathology, Bronx, NY, United States

Julia A. Elvin

Department of Pathology and Diagnostic Medicine, Foundation Medicine Inc., Cambridge, MA, United States

Sara S. Isani

Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States

Ken Y. Lin

Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States